Thursday, May 14, 2026
← Back to archivePolicy
Policy•Fierce Biotech•May 12, 2026
FDA Commissioner Marty Makary to resign, capping turbulent tenure
background ▾
- •FDA leadership instability continues under the Trump administration with Makary's forced resignation after just 9 months, signaling potential ongoing volatility in regulatory direction and personnel
- •Despite Makary's departure, his key policy initiatives (expedited clinical trial pathways, CNPV pilot, plausible mechanism framework) are expected to survive and receive continued Trump administration backing
- •Monitor the permanent FDA commissioner appointment and whether the successor will stabilize the agency or continue the pattern of rapid leadership changes and alleged inconsistent regulatory standards that have frustrated industry
mifepristone
→ Read original articlePolicy•Fierce Pharma•May 14, 2026
As Trump arrives in China, Big Pharma CEOs are notably absent
background ▾
- •Pharmaceutical industry leadership is absent from Trump's China trade delegation, marking an unusual gap in a sector typically active in such diplomatic-commercial missions
- •The absence may reflect industry concerns about US-China trade relations, IP protections, or uncertainty about pharma's role in broader trade negotiations
Policy•Fierce Pharma•May 14, 2026
Takeda, slimming down for 'new era,' plots 4,500 layoffs in latest restructuring drive
background ▾
- •Takeda plans 4,500 layoffs (fiscal 2026) with $633M in annual gross savings but $1.07B restructuring charge
- •Part of broader multi-year restructuring to position company for 'new era'—suggests ongoing strategic repositioning beyond simple cost-cutting
Takeda Pharmaceutical
→ Read original articlePolicy•Fierce Pharma•May 14, 2026
BeOne Medicines’ Brukinsa TV ad 'Clarity' hit by FDA over 'misleading suggestions'
background ▾
- •FDA enforcement action on Brukinsa advertising for unsubstantiated claims suggests BeOne may need to revise promotional materials and messaging strategy
- •Untitled letters are warning communications that typically precede more formal enforcement if the company does not respond adequately
BeOne MedicinesBrukinsa
→ Read original articlePolicy•STAT News•May 14, 2026
Opinion: Using AI in addiction medicine could be particularly risky
background ▾
- •Patient-facing AI conversational agents that simulate empathy risk creating false emotional attachments that could displace critical human relationships and community support essential to addiction recovery
- •Addiction medicine providers should distinguish between beneficial provider-facing AI tools (ambient listening, documentation efficiency) and potentially harmful patient-facing systems that compete for limited emotional engagement capacity in vulnerable populations
- •Emerging psychological research from Stanford and Brown institutions documents how large language models can exploit human wiring for perceived empathy, creating particular risks in addiction treatment where avoidance and substitution patterns sustain disease
Market Access
Market Access•Fierce Pharma•May 14, 2026
BeOne's Venclexta challenger Beqalzi nets FDA approval as first BCL-2 for mantle cell lymphoma
background ▾
- •Beqalzi is the first FDA-approved BCL-2 inhibitor specifically for mantle cell lymphoma, ending Venclexta's monopoly in this indication and potentially opening competitive pricing pressure
- •Market penetration will hinge on payer coverage, clinical differentiation, and whether BeOne can establish cost or efficacy advantages over the entrenched Venclexta standard
- •Monitor early adoption rates, payer formulary placements, and any label expansions or head-to-head trial data that could reshape competitive positioning
BeOne MedicinesAbbVieBeqalziVenclexta
→ Read original articleMarket Access•Fierce Biotech•May 13, 2026
Valneva to lay off up to 15% of workforce in face of ‘adverse trend’ in travel vaccines
background ▾
- •Valneva's Q1 2026 revenue collapsed 37% year-over-year to €30.9M, with full-year guidance cut from €145-160M to €135-150M, primarily due to geopolitical headwinds suppressing travel vaccine demand
- •The company faces a perfect storm: Pfizer-partnered Lyme disease vaccine missed its pivotal trial primary endpoint; chikungunya vaccine Ixchiq was withdrawn from the US market after FDA cited an encephalitis death 'directly attributable' to the vaccine
- •Watch for: regulatory decisions on the Lyme disease vaccine (critical to survival strategy), execution of 25-35% cost reduction plan, and whether geopolitical travel disruptions stabilize—failure on any front threatens viability
ValnevaPfizerBavarian NordicIxiaroDukoralIxchiq
→ Read original articleMarket Access•Fierce Biotech•May 13, 2026
With $1B Novo deal and diabetes ambitions undimmed, Lexicon is in ‘good shape to go crazy’
background ▾
- •Lexicon secured a $1 billion biobucks deal with Novo Nordisk for LX9851, validating the company's strategic pivot toward first-in-class candidates in high-value indications
- •CEO Michael Exton's radical restructuring—eliminating 160 employees, closing commercial operations, and cutting Inpefa/Zynquista promotion—reflects a deliberate shift from marketed drugs facing market access headwinds to earlier-stage pipeline-focused development
- •Watch for LX9851 clinical progress, pilavapadin repositioning efforts, and whether Lexicon can maintain financial stability through the Novo partnership while advancing other pipeline candidates
Lexicon PharmaceuticalsNovo NordiskNovartisInpefaZynquistaXermelo
→ Read original articleMarket Access•Fierce Pharma•May 14, 2026
Merck KGaA looks to M&A to bolster its 'rather slim' pipeline
background ▾
- •New leadership at Merck KGaA is explicitly pursuing M&A strategy to address acknowledged pipeline weakness in early-to-mid stage development
- •What to watch: Announcement of specific M&A targets or partnerships over coming quarters; performance of Merck KGaA's existing marketed products while pipeline is bolstered
Merck KGaA
→ Read original articleMarket Access•Fierce Pharma•May 14, 2026
Haleon tackles sports injuries with latest soccer play
background ▾
- •Haleon is pursuing sports medicine as a market access channel, targeting athletes and sports organizations in Europe
Haleon
→ Read original articleClinical Trials
Clinical Trials•Fierce Pharma•May 14, 2026
Novo, Lilly tout respective early response and weight loss maintenance data as GLP-1 rivalry intensifies
background ▾
- •Lilly and Novo are leveraging distinct pharmacologic or dosing advantages—maintenance vs. rapid onset—to differentiate their GLP-1 portfolios in a market with multiple effective competitors
- •These findings suggest potential for sequential or patient-tailored use of GLP-1 agents based on phase of weight loss journey, widening commercial addressability
- •Monitor upcoming head-to-head trial data and real-world evidence studies to determine whether claimed differences translate into meaningful clinical or market advantages
Eli LillyNovo Nordisktirzepatidesemaglutide
→ Read original articleClinical Trials•Endpoints News•May 13, 2026
After an apparent cure, a gene editing company struggles to repeat the magic
background ▾
- •iECURE's initial patient cure cannot yet be replicated in follow-up cases, raising questions about treatment consistency and mechanism durability
- •Reproducibility is essential for gene therapy regulatory approval; failure to repeat early success could derail the program's development trajectory
- •The outcome will inform investor appetite for gene therapy startups and may influence how regulators evaluate single-case 'cure' claims in rare disease programs
iECURE
→ Read original articleClinical Trials•Endpoints News•May 13, 2026
Abeona pivots to T cells; AstraZeneca's rare disease drug passes Phase 3
background ▾
- •Abeona's pivot from gene therapy to T cell oncology represents a significant strategic shift with implications for its commercial priorities and R&D resource allocation
- •AstraZeneca's Phase 3 success in rare disease provides a potential near-term regulatory filing opportunity and validates the compound's clinical profile
- •Multiple pipeline movements across the industry suggest ongoing portfolio optimization and competitive repositioning in both cell therapy and rare disease spaces
Abeona TherapeuticsAstraZenecaAmicus Therapeutics
→ Read original articleClinical Trials•Endpoints News•May 13, 2026
Tessera reveals strongest data yet for in vivo sickle cell therapy
background ▾
- •Tessera's in vivo gene editing approach for sickle cell disease demonstrates competitive efficacy versus established cell therapies while potentially offering superior delivery/logistics
- •The in vivo modality could address key limitations of current ex vivo cell therapy approaches (manufacturing complexity, patient eligibility, accessibility)
- •Watch for detailed phase 2/3 data readout, regulatory path forward, and head-to-head comparative positioning against Bluebird, CRISPR Therapeutics, and Vertex offerings
Tessera TherapeuticsTessera gene editing therapy (sickle cell disease, investigational)
→ Read original article